Entinostat | MS-275;SNDX-275;MS 2275 | 恩替诺特 (MS-275) | Apoptosis Inducer | HDAC

首页 / / / / Entinostat/恩替诺特

Entinostat/恩替诺特 {[allProObj[0].p_purity_real_show]}

货号：A122285 同义名： 恩替诺特 (MS-275) / MS-275; SNDX-275

Entinostat是一种口服选择性I类HDAC抑制剂，对HDAC1、HDAC2和HDAC3的IC50值分别为243 nM、453 nM和248 nM。

Entinostat/恩替诺特化学结构
CAS号：209783-80-2

Entinostat/恩替诺特 3D分子结构
CAS号：209783-80-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Entinostat/恩替诺特纯度/质量文件产品仅供科研

货号：A122285 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-A (Maize), IC50: 100 nM HD1-B (Maize), IC50: 3.4 μM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												NF-κB,Nrf2	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Entinostat/恩替诺特生物活性

靶点	HDAC3 HDAC3, IC50:1.7 μM HDAC1 HDAC1, IC50:0.51 μM
描述	The inhibition of class I HDACs increases the acetylation of histone proteins, which affects the tertiary chromatin structure and leads to altered expression of genes involved in cell proliferation, apoptosis and differentiation. Thus it makes a key role for inhibition of HDACs in anti-proliferation of tumor cells. Entinostat (MS-275) is a selective HDAC 1/2/3 inhibitor with IC50 values of 0.163, 0.396 and 0.605 μM, respectively^[1]. A significant increased level of acetylated histone H3 can be observed in PBMCs treated with 5 nM entinostat for 24h. This hyperacetylation effect can also be observed in total cell extracts from PBMCs and tumor tissues in the mouse B16F10 melanoma models when treated orally with 50 mg/kg/day entinostat in a time-dependent manner. The anti-tumor efficacy of entinostat in vivo was proved in several experimental human tumor models with dose of 40 - 50 mg/kg/day, p.o., including MCF7, MDA-MB231, OVCAR3, HeLa-MaTu, DU145, H460, A549, LXF, HT29, HCT116, CAPAN1, 786-O and SK-Mel28 tumor bearing mice. A lot of gene-expression regulated through HDAC inhibition by entinostat are involved in this anti-tumor efficacy, including up-regulation of p21 in cell cycle, H2B in chromatin, CAECAM5 in cell communication and alpha-Tubulin in cytoskeleton, as well as down-regulation of TNFSF13 in apoptosis, HIF1-alpha in angiogenesis, and CTPS2 in metabolism^[2]. Entinostat is in phase III for hormone receptor-positive advanced breast cancer and is in phase II for lung cancer, breast cancer, and Hodgkin lymphoma^[3].
作用机制	The crystal structure of the HDAC2-benzamide complex reveals that the entinostat coordinates to the catalytic Zn2+ ion through both the carbonyl and amino groups to form an unusual 7-membered ring chelate complex^[4].

Entinostat/恩替诺特细胞实验

Cell Line MCF7 MDA-MB-231b SKOV3 OVCAR5 Panc1 cells BxPC3 cells L3.6 cells HMC3 microglia-like cells HaCaT cells human neuroendocrine SCLC cells KU-OC-031065 KU-OC-033697 OVCAR-3 SKOV-3 HNT34 UCSD/AML1 MOLM1 MEWO SKMEL2 Hs695T MCA205 cells	Concentration	Treated Time	Description	References
MCF7	0.5μM, 5μM	1, 3, 6, 12, or 24 h	significantly increased LIFR mRNA expression	Oncogene. 2021 Aug;40(34):5314-5326.
MDA-MB-231b	0.5μM, 5μM	1, 3, 6, 12, or 24 h	significantly increased LIFR mRNA expression	Oncogene. 2021 Aug;40(34):5314-5326.
SKOV3	5 μM	12 h	To investigate the effect of Entinostat combined with Niraparib on HRD-EXCUTE signature, results showed that the combination significantly enhanced the HRD-EXCUTE signature.	Int J Biol Sci. 2023 Mar 21;19(6):1846-1860.
OVCAR5	5 μM	12 h	To investigate the effect of Entinostat combined with Olaparib on HRD-EXCUTE signature, results showed that the combination significantly enhanced the HRD-EXCUTE signature.	Int J Biol Sci. 2023 Mar 21;19(6):1846-1860.
Panc1 cells	500 nM	24 or 72 h	To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
BxPC3 cells	500 nM	24 or 72 h	To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
L3.6 cells	500 nM	24 or 72 h	To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
HMC3 microglia-like cells	10µM	24 h	To assess the effect of Entinostat on DAM marker gene expression, results showed significant upregulation of SPP1 and CD9 expression	bioRxiv [Preprint]. 2024 Oct 12:2024.10.11.617544.
HaCaT cells	10 μM	48 h	To examine the effect of the HDAC inhibitor entinostat on DNA methylation, it was found that BG4 signal significantly increased in open chromatin promoter regions, and methylation levels at BG4 peaks were significantly reduced.	Nat Struct Mol Biol. 2018 Oct;25(10):951-957.
human neuroendocrine SCLC cells	2.5 μM	24 h	To investigate the effects of Entinostat on cell cycle and DNA damage in SCLC cells.	Clin Cancer Res. 2023 Nov 14;29(22):4644-4659.
KU-OC-031065	0.25 μM	72 h	Entinostat combined with olaparib significantly reduced the viability of KU-OC-031065 cells, showing synergistic effects.	Gynecol Oncol. 2021 Jul;162(1):163-172.
KU-OC-033697	0.25 μM	72 h	Entinostat combined with olaparib significantly reduced the viability of KU-OC-033697 cells, showing synergistic effects.	Gynecol Oncol. 2021 Jul;162(1):163-172.
OVCAR-3	0.25 μM	72 h	Entinostat combined with olaparib significantly reduced the viability of OVCAR-3 cells, showing synergistic effects.	Gynecol Oncol. 2021 Jul;162(1):163-172.
SKOV-3	0.25 μM	72 h	Entinostat combined with olaparib significantly reduced the viability of HR-proficient ovarian cancer cells, showing synergistic effects.	Gynecol Oncol. 2021 Jul;162(1):163-172.
HNT34	1 μM	72 h	To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation.	Nat Commun. 2024 Jun 4;15(1):4739.
UCSD/AML1	1 μM	72 h	To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation.	Nat Commun. 2024 Jun 4;15(1):4739.
MOLM1	1 μM	72 h	To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation.	Nat Commun. 2024 Jun 4;15(1):4739.
MEWO	1μM	72 h	Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number.	Cancer Discov. 2019 Apr;9(4):526-545.
SKMEL2	1μM	72 h	Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number.	Cancer Discov. 2019 Apr;9(4):526-545.
Hs695T	1μM	72 h	Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number.	Cancer Discov. 2019 Apr;9(4):526-545.
MCA205 cells	10 µM	6 h	Entinostat treatment upregulated the mRNA expression of Cxcl9, 10, 11	Cancer Immunol Res. 2023 May 3;11(5):657-673.

Entinostat/恩替诺特动物实验

Species Mice Mice SCID mice Mice Mice Mice	Animal Model HRD ovarian cancer model MCF7 orthotopic inoculation model H841 xenograft model SKOV-3-IP-Luc xenograft model BRAF-mutant melanoma xenograft model MC38 and MCA205 tumor models	Administration	Dosage	Frequency	Description	References
Mice	HRD ovarian cancer model	Intraperitoneal injection	5 mg/kg	Weekly for 4 weeks	To investigate the effect of Entinostat combined with Niraparib on HRD ovarian cancer model, results showed that the combination significantly inhibited tumor growth and enhanced HRD-EXCUTE signature.	Int J Biol Sci. 2023 Mar 21;19(6):1846-1860.
Mice	MCF7 orthotopic inoculation model		10mg/kg	5 days/week until sacrifice	Significantly reduced MCF7 primary tumor growth	Oncogene. 2021 Aug;40(34):5314-5326.
SCID mice	H841 xenograft model	Entinostat: oral gavage, cisplatin: intraperitoneal injection	25 mg/kg	Entinostat: twice a week, cisplatin: once a week, for 30 days	Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Tumor weights and intratumoral Pt content were significantly higher in the combination group, which also showed enhanced apoptosis and necrosis.	Clin Cancer Res. 2023 Nov 14;29(22):4644-4659.
Mice	SKOV-3-IP-Luc xenograft model	Oral gavage	15 mg/kg	Once weekly for two weeks	Entinostat combined with olaparib significantly reduced peritoneal metastases in the SKOV-3 xenograft model and prolonged survival in the CCNE1-amplified HR-proficient PDX model.	Gynecol Oncol. 2021 Jul;162(1):163-172.
Mice	BRAF-mutant melanoma xenograft model	Intraperitoneal injection	1mg/kg	Once weekly for 2 weeks	Entinostat combined with BRAF/MEK inhibitors significantly enhanced tumor regression, with an average 70% reduction in tumor volume.	Cancer Discov. 2019 Apr;9(4):526-545.
Mice	MC38 and MCA205 tumor models	Oral	30 mg/kg	Three times per week for 28 days	Entinostat significantly suppressed the growth of MC38 and MCA205 tumors in immunocompetent mice but not in immunodeficient mice	Cancer Immunol Res. 2023 May 3;11(5):657-673.

Entinostat/恩替诺特动物研究

Dose

Mice: min = 1 mg/kg^[5] (i.p.), max = 49 mg/kg^[6] (p.o.)

Administration

i.p., p.o.

Pharmacokinetics

Animal	Rats^[7]
Dose	15 mg/kg
Administration	p.o.
C_max	8141.6 ± 2655.5 ng/ml
T_1/2	9.8 ± 5.2 h
AUC_0→∞	13368.3 ± 3492.3 ng/ml·h
AUC_0→t	13006.7 ± 3573.6 ng/ml·h
CL	1.2 ± 0.2 L/h/kg
T_max	0.4 ± 0.2 h
MRT_0→∞	3.4 ± 1.4 h
V_d	16.9 ± 10.7 L/kg
MRT_0→t	2.2 ± 0.3 h

Entinostat/恩替诺特临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03280563	Breast Neoplasms	Phase 1 Phase 2	Recruiting	October 7, 2022	-
NCT02623751	Breast Cancer	Phase 1	Active, not recruiting	February 2019	Japan ... 展开 >> Chikusa-ku, Aichi, Japan Chuo-ku, Osaka, Japan Chuo-ku, Tokyo, Japan 收起 <<
NCT00823290	Hepatocellular Carcinoma	Phase 1	Unknown	December 2010	Germany ... 展开 >> Department of Medicine 1, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Matthias Ocker, MD +49-6421-58 ext 68931 Matthias.Ocker@staff.uni-marburg.de Contact: Susanne Gahr, MD +49-9131-85 ext 35000 susanne.gahr@uk-erlangen.de Principal Investigator: Deike Strobel, MD 收起 <<

Entinostat/恩替诺特参考文献

[1]Gao S, Zang J, et al. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. Bioorg Med Chem. 2017 Jun 15;25(12):2981-2994.

[2]Hess-Stumpp H, Bracker TU, et al. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int J Biochem Cell Biol. 2007;39(7-8):1388-405. Epub 2007 Feb 16.

[3]Yoon S, Eom GH, et al. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016 Jan;52(1):1-11.

[4]Lombardi PM, Cole KE, et al. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol. 2011 Dec;21(6):735-43.

[5]Vendetti FP, Topper M, et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015 Jan 1;6(1):56-70.

[6]Saito A, Yamashita T, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7.

[7]Yang X, Zhang Q, et al. Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. Xenobiotica. 2014 Nov;44(11):1009-13.

Entinostat/恩替诺特实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.28mL

2.66mL

1.33mL

26.57mL

5.31mL

2.66mL

Entinostat/恩替诺特技术信息

CAS号	209783-80-2
分子式	C₂₁H₂₀N₄O₃
分子量	376.41
SMILES Code	O=C(OCC1=CC=CN=C1)NCC2=CC=C(C(NC3=CC=CC=C3N)=O)C=C2
MDL No.	MFCD08272435

别名	恩替诺特 (MS-275) ;MS-275; SNDX-275; MS 2275
运输	蓝冰
InChI Key	INVTYAOGFAGBOE-UHFFFAOYSA-N
Pubchem ID	4261

存储条件

In solvent -20°C:3-6个月-80°C:12个月

溶解方案

细胞实验：

DMSO: 50 mg/mL(132.83 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

方案四

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

HDAC3	HDAC3, IC50:1.7 μM
HDAC1	HDAC1, IC50:0.51 μM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

697	Growth Inhibition Assay	IC50=0.09976 μM	SANGER
8-MG-BA	Growth Inhibition Assay	IC50=1.28866 μM	SANGER
A101D	Growth Inhibition Assay	IC50=0.403 μM	SANGER
A253	Growth Inhibition Assay	IC50=8.84661 μM	SANGER
A388	Growth Inhibition Assay	IC50=1.51945 μM	SANGER
A3-KAW	Growth Inhibition Assay	IC50=0.17627 μM	SANGER
A4-Fuk	Growth Inhibition Assay	IC50=1.15364 μM	SANGER
ACN	Growth Inhibition Assay	IC50=0.51028 μM	SANGER
ALL-PO	Growth Inhibition Assay	IC50=0.06355 μM	SANGER
ARH-77	Growth Inhibition Assay	IC50=0.38193 μM	SANGER
ATN-1	Growth Inhibition Assay	IC50=0.30576 μM	SANGER
BB30-HNC	Growth Inhibition Assay	IC50=1.38978 μM	SANGER
BB49-HNC	Growth Inhibition Assay	IC50=2.9248 μM	SANGER
BB65-RCC	Growth Inhibition Assay	IC50=3.97547 μM	SANGER
BC-1	Growth Inhibition Assay	IC50=0.43403 μM	SANGER
BC-3	Growth Inhibition Assay	IC50=0.78308 μM	SANGER
BE-13	Growth Inhibition Assay	IC50=0.49661 μM	SANGER
Becker	Growth Inhibition Assay	IC50=4.37312 μM	SANGER
BL-41	Growth Inhibition Assay	IC50=0.56889 μM	SANGER
BL-70	Growth Inhibition Assay	IC50=0.85702 μM	SANGER
BT-474	Growth Inhibition Assay	IC50=1.51764 μM	SANGER
BV-173	Growth Inhibition Assay	IC50=0.37121 μM	SANGER
C2BBe1	Growth Inhibition Assay	IC50=12.6131 μM	SANGER
CA46	Growth Inhibition Assay	IC50=31.6936 μM	SANGER
CAL-148	Growth Inhibition Assay	IC50=1.32542 μM	SANGER
Calu-6	Growth Inhibition Assay	IC50=8.99042 μM	SANGER
CAS-1	Growth Inhibition Assay	IC50=12.3631 μM	SANGER
CCRF-CEM	Growth Inhibition Assay	IC50=0.74661 μM	SANGER
CESS	Growth Inhibition Assay	IC50=0.81197 μM	SANGER
CGTH-W-1	Growth Inhibition Assay	IC50=2.42267 μM	SANGER
CHP-126	Growth Inhibition Assay	IC50=0.40231 μM	SANGER
CMK	Growth Inhibition Assay	IC50=0.35727 μM	SANGER
COLO-320-HSR	Growth Inhibition Assay	IC50=2.85641 μM	SANGER
COLO-668	Growth Inhibition Assay	IC50=8.27786 μM	SANGER
COLO-684	Growth Inhibition Assay	IC50=5.99494 μM	SANGER
COLO-829	Growth Inhibition Assay	IC50=1.53564 μM	SANGER
COR-L279	Growth Inhibition Assay	IC50=0.70996 μM	SANGER
COR-L88	Growth Inhibition Assay	IC50=0.22959 μM	SANGER
CP66-MEL	Growth Inhibition Assay	IC50=2.4777 μM	SANGER
CPC-N	Growth Inhibition Assay	IC50=0.80524 μM	SANGER
CRO-AP2	Growth Inhibition Assay	IC50=0.16889 μM	SANGER
CTB-1	Growth Inhibition Assay	IC50=3.05376 μM	SANGER
CTV-1	Growth Inhibition Assay	IC50=1.27425 μM	SANGER
CW-2	Growth Inhibition Assay	IC50=0.65794 μM	SANGER
D-247MG	Growth Inhibition Assay	IC50=12.7952 μM	SANGER
D-263MG	Growth Inhibition Assay	IC50=6.08895 μM	SANGER
D-283MED	Growth Inhibition Assay	IC50=14.6271 μM	SANGER
D-502MG	Growth Inhibition Assay	IC50=5.00416 μM	SANGER
D-542MG	Growth Inhibition Assay	IC50=1.89373 μM	SANGER
Daudi	Growth Inhibition Assay	IC50=0.77681 μM	SANGER
DB	Growth Inhibition Assay	IC50=1.70353 μM	SANGER
DEL	Growth Inhibition Assay	IC50=0.37487 μM	SANGER
DG-75	Growth Inhibition Assay	IC50=2.27148 μM	SANGER
DJM-1	Growth Inhibition Assay	IC50=3.59899 μM	SANGER
DMS-153	Growth Inhibition Assay	IC50=0.97469 μM	SANGER
DMS-79	Growth Inhibition Assay	IC50=2.54103 μM	SANGER
DSH1	Growth Inhibition Assay	IC50=0.28708 μM	SANGER
DU-4475	Growth Inhibition Assay	IC50=0.58703 μM	SANGER
EB-3	Growth Inhibition Assay	IC50=3.99633 μM	SANGER
ECC12	Growth Inhibition Assay	IC50=0.70086 μM	SANGER
ECC4	Growth Inhibition Assay	IC50=3.97195 μM	SANGER
EHEB	Growth Inhibition Assay	IC50=0.92585 μM	SANGER
EKVX	Growth Inhibition Assay	IC50=6.46321 μM	SANGER
EM-2	Growth Inhibition Assay	IC50=0.24079 μM	SANGER
EoL-1-cell	Growth Inhibition Assay	IC50=11.7682 μM	SANGER
ES1	Growth Inhibition Assay	IC50=0.11255 μM	SANGER
ES3	Growth Inhibition Assay	IC50=43.1339 μM	SANGER
ES4	Growth Inhibition Assay	IC50=0.85868 μM	SANGER
ES6	Growth Inhibition Assay	IC50=0.96437 μM	SANGER
ES7	Growth Inhibition Assay	IC50=1.80302 μM	SANGER
ES8	Growth Inhibition Assay	IC50=0.36022 μM	SANGER
ETK-1	Growth Inhibition Assay	IC50=1.78879 μM	SANGER
EVSA-T	Growth Inhibition Assay	IC50=1.18114 μM	SANGER
EW-1	Growth Inhibition Assay	IC50=2.77083 μM	SANGER
EW-11	Growth Inhibition Assay	IC50=44.8218 μM	SANGER
EW-12	Growth Inhibition Assay	IC50=8.40803 μM	SANGER
EW-16	Growth Inhibition Assay	IC50=1.9272 μM	SANGER
EW-18	Growth Inhibition Assay	IC50=14.448 μM	SANGER
EW-22	Growth Inhibition Assay	IC50=42.2885 μM	SANGER
EW-24	Growth Inhibition Assay	IC50=6.2851 μM	SANGER
EW-3	Growth Inhibition Assay	IC50=12.2463 μM	SANGER
GB-1	Growth Inhibition Assay	IC50=1.93866 μM	SANGER
GCIY	Growth Inhibition Assay	IC50=10.5924 μM	SANGER
GDM-1	Growth Inhibition Assay	IC50=0.88687 μM	SANGER
GI-1	Growth Inhibition Assay	IC50=2.92957 μM	SANGER
GI-ME-N	Growth Inhibition Assay	IC50=4.06399 μM	SANGER
GOTO	Growth Inhibition Assay	IC50=0.95076 μM	SANGER
GR-ST	Growth Inhibition Assay	IC50=1.5682 μM	SANGER
GT3TKB	Growth Inhibition Assay	IC50=4.33268 μM	SANGER
HAL-01	Growth Inhibition Assay	IC50=1.16943 μM	SANGER
HC-1	Growth Inhibition Assay	IC50=0.50473 μM	SANGER
HCC1187	Growth Inhibition Assay	IC50=4.89657 μM	SANGER
HCC1599	Growth Inhibition Assay	IC50=0.5157 μM	SANGER
HCC2157	Growth Inhibition Assay	IC50=1.42691 μM	SANGER
HCC2218	Growth Inhibition Assay	IC50=1.16641 μM	SANGER
HCC2998	Growth Inhibition Assay	IC50=0.7836 μM	SANGER
HCE-T	Growth Inhibition Assay	IC50=0.87171 μM	SANGER
HDLM-2	Growth Inhibition Assay	IC50=1.68281 μM	SANGER
HD-MY-Z	Growth Inhibition Assay	IC50=1.75234 μM	SANGER
HEL	Growth Inhibition Assay	IC50=0.31348 μM	SANGER
HH	Growth Inhibition Assay	IC50=0.98959 μM	SANGER
HL-60	Growth Inhibition Assay	IC50=0.54261 μM	SANGER
HOP-62	Growth Inhibition Assay	IC50=0.48358 μM	SANGER
HT	Growth Inhibition Assay	IC50=2.10454 μM	SANGER
HT-144	Growth Inhibition Assay	IC50=0.30256 μM	SANGER
HUTU-80	Growth Inhibition Assay	IC50=1.79508 μM	SANGER
IST-MEL1	Growth Inhibition Assay	IC50=1.17659 μM	SANGER
IST-MES1	Growth Inhibition Assay	IC50=3.18279 μM	SANGER
IST-SL1	Growth Inhibition Assay	IC50=0.77348 μM	SANGER
IST-SL2	Growth Inhibition Assay	IC50=2.00262 μM	SANGER
JAR	Growth Inhibition Assay	IC50=0.87827 μM	SANGER
JiyoyeP-2003	Growth Inhibition Assay	IC50=1.3539 μM	SANGER
J-RT3-T3-5	Growth Inhibition Assay	IC50=0.33716 μM	SANGER
JVM-2	Growth Inhibition Assay	IC50=21.4133 μM	SANGER
K5	Growth Inhibition Assay	IC50=0.47025 μM	SANGER
K-562	Growth Inhibition Assay	IC50=1.39219 μM	SANGER
KALS-1	Growth Inhibition Assay	IC50=0.70492 μM	SANGER
KARPAS-299	Growth Inhibition Assay	IC50=0.58504 μM	SANGER
KARPAS-422	Growth Inhibition Assay	IC50=1.45358 μM	SANGER
KARPAS-45	Growth Inhibition Assay	IC50=0.27833 μM	SANGER
KE-37	Growth Inhibition Assay	IC50=0.64276 μM	SANGER
KG-1	Growth Inhibition Assay	IC50=1.61901 μM	SANGER
KGN	Growth Inhibition Assay	IC50=2.76876 μM	SANGER
KINGS-1	Growth Inhibition Assay	IC50=4.31432 μM	SANGER
KM12	Growth Inhibition Assay	IC50=1.647 μM	SANGER
KM-H2	Growth Inhibition Assay	IC50=1.5667 μM	SANGER
KMOE-2	Growth Inhibition Assay	IC50=2.87711 μM	SANGER
KNS-42	Growth Inhibition Assay	IC50=35.9624 μM	SANGER
KNS-81-FD	Growth Inhibition Assay	IC50=5.90694 μM	SANGER
KS-1	Growth Inhibition Assay	IC50=0.88096 μM	SANGER
KU812	Growth Inhibition Assay	IC50=1.69605 μM	SANGER
KURAMOCHI	Growth Inhibition Assay	IC50=1.77207 μM	SANGER
L-363	Growth Inhibition Assay	IC50=0.56657 μM	SANGER
L-428	Growth Inhibition Assay	IC50=2.48521 μM	SANGER
L-540	Growth Inhibition Assay	IC50=1.10604 μM	SANGER
LAMA-84	Growth Inhibition Assay	IC50=0.77567 μM	SANGER
LAN-6	Growth Inhibition Assay	IC50=2.01966 μM	SANGER
LB1047-RCC	Growth Inhibition Assay	IC50=1.63459 μM	SANGER
LB2241-RCC	Growth Inhibition Assay	IC50=1.28663 μM	SANGER
LB2518-MEL	Growth Inhibition Assay	IC50=0.93284 μM	SANGER
LB373-MEL-D	Growth Inhibition Assay	IC50=2.26902 μM	SANGER
LB647-SCLC	Growth Inhibition Assay	IC50=0.3673 μM	SANGER
LB771-HNC	Growth Inhibition Assay	IC50=6.92301 μM	SANGER
LB831-BLC	Growth Inhibition Assay	IC50=1.83563 μM	SANGER
LB996-RCC	Growth Inhibition Assay	IC50=1.47103 μM	SANGER
LC-1F	Growth Inhibition Assay	IC50=1.12007 μM	SANGER
LC-2-ad	Growth Inhibition Assay	IC50=0.53663 μM	SANGER
LC4-1	Growth Inhibition Assay	IC50=0.84007 μM	SANGER
LOUCY	Growth Inhibition Assay	IC50=0.63364 μM	SANGER
LOXIMVI	Growth Inhibition Assay	IC50=1.9328 μM	SANGER
LP-1	Growth Inhibition Assay	IC50=1.29947 μM	SANGER
LS-1034	Growth Inhibition Assay	IC50=14.3975 μM	SANGER
LS-123	Growth Inhibition Assay	IC50=2.34936 μM	SANGER
LS-411N	Growth Inhibition Assay	IC50=1.30998 μM	SANGER
LS-513	Growth Inhibition Assay	IC50=0.44501 μM	SANGER
LU-134-A	Growth Inhibition Assay	IC50=0.57073 μM	SANGER
LU-139	Growth Inhibition Assay	IC50=0.3351 μM	SANGER
LU-165	Growth Inhibition Assay	IC50=0.61812 μM	SANGER
LU-65	Growth Inhibition Assay	IC50=4.15332 μM	SANGER
LXF-289	Growth Inhibition Assay	IC50=0.95901 μM	SANGER
MC116	Growth Inhibition Assay	IC50=1.43615 μM	SANGER
MDA-MB-134-VI	Growth Inhibition Assay	IC50=1.28577 μM	SANGER
MEG-01	Growth Inhibition Assay	IC50=1.22118 μM	SANGER
MFH-ino	Growth Inhibition Assay	IC50=3.46589 μM	SANGER
MHH-CALL-2	Growth Inhibition Assay	IC50=1.24721 μM	SANGER
MHH-NB-11	Growth Inhibition Assay	IC50=0.43453 μM	SANGER
MHH-PREB-1	Growth Inhibition Assay	IC50=0.60719 μM	SANGER
ML-2	Growth Inhibition Assay	IC50=2.32855 μM	SANGER
MLMA	Growth Inhibition Assay	IC50=1.88234 μM	SANGER
MMAC-SF	Growth Inhibition Assay	IC50=9.97904 μM	SANGER
MN-60	Growth Inhibition Assay	IC50=4.1087 μM	SANGER
MOLT-13	Growth Inhibition Assay	IC50=0.3381 μM	SANGER
MOLT-16	Growth Inhibition Assay	IC50=0.41017 μM	SANGER
MOLT-4	Growth Inhibition Assay	IC50=1.03454 μM	SANGER
MONO-MAC-6	Growth Inhibition Assay	IC50=0.38776 μM	SANGER
MPP-89	Growth Inhibition Assay	IC50=2.33145 μM	SANGER
MRK-nu-1	Growth Inhibition Assay	IC50=0.43153 μM	SANGER
MSTO-211H	Growth Inhibition Assay	IC50=1.47987 μM	SANGER
MV-4-11	Growth Inhibition Assay	IC50=0.53041 μM	SANGER
MZ1-PC	Growth Inhibition Assay	IC50=3.61624 μM	SANGER
MZ2-MEL	Growth Inhibition Assay	IC50=14.9696 μM	SANGER
MZ7-mel	Growth Inhibition Assay	IC50=0.56105 μM	SANGER
NALM-6	Growth Inhibition Assay	IC50=0.6486 μM	SANGER
NB1	Growth Inhibition Assay	IC50=1.27732 μM	SANGER
NB10	Growth Inhibition Assay	IC50=2.41092 μM	SANGER
NB12	Growth Inhibition Assay	IC50=0.31756 μM	SANGER
NB13	Growth Inhibition Assay	IC50=0.66817 μM	SANGER
NB14	Growth Inhibition Assay	IC50=0.72617 μM	SANGER
NB17	Growth Inhibition Assay	IC50=0.5438 μM	SANGER
NB5	Growth Inhibition Assay	IC50=1.65677 μM	SANGER
NB6	Growth Inhibition Assay	IC50=3.55563 μM	SANGER
NB69	Growth Inhibition Assay	IC50=0.59825 μM	SANGER
NB7	Growth Inhibition Assay	IC50=5.14112 μM	SANGER
NCCIT	Growth Inhibition Assay	IC50=0.38649 μM	SANGER
NCI-H1092	Growth Inhibition Assay	IC50=2.05124 μM	SANGER
NCI-H1155	Growth Inhibition Assay	IC50=3.70947 μM	SANGER
NCI-H1304	Growth Inhibition Assay	IC50=3.00511 μM	SANGER
NCI-H1355	Growth Inhibition Assay	IC50=2.11792 μM	SANGER
NCI-H1395	Growth Inhibition Assay	IC50=20.6703 μM	SANGER
NCI-H1417	Growth Inhibition Assay	IC50=0.12974 μM	SANGER
NCI-H1436	Growth Inhibition Assay	IC50=4.18333 μM	SANGER
NCI-H1522	Growth Inhibition Assay	IC50=2.21723 μM	SANGER
NCI-H1581	Growth Inhibition Assay	IC50=22.4148 μM	SANGER
NCI-H1648	Growth Inhibition Assay	IC50=6.67557 μM	SANGER
NCI-H1694	Growth Inhibition Assay	IC50=4.13405 μM	SANGER
NCI-H187	Growth Inhibition Assay	IC50=0.49227 μM	SANGER
NCI-H1882	Growth Inhibition Assay	IC50=2.67562 μM	SANGER
NCI-H1963	Growth Inhibition Assay	IC50=0.11579 μM	SANGER
NCI-H2081	Growth Inhibition Assay	IC50=11.7786 μM	SANGER
NCI-H209	Growth Inhibition Assay	IC50=0.40613 μM	SANGER
NCI-H2107	Growth Inhibition Assay	IC50=1.35883 μM	SANGER
NCI-H2126	Growth Inhibition Assay	IC50=8.89319 μM	SANGER
NCI-H2141	Growth Inhibition Assay	IC50=3.16566 μM	SANGER
NCI-H2171	Growth Inhibition Assay	IC50=1.34502 μM	SANGER
NCI-H2196	Growth Inhibition Assay	IC50=4.05625 μM	SANGER
NCI-H2227	Growth Inhibition Assay	IC50=3.02079 μM	SANGER
NCI-H23	Growth Inhibition Assay	IC50=9.17746 μM	SANGER
NCI-H345	Growth Inhibition Assay	IC50=2.33277 μM	SANGER
NCI-H446	Growth Inhibition Assay	IC50=42.7853 μM	SANGER
NCI-H510A	Growth Inhibition Assay	IC50=2.04502 μM	SANGER
NCI-H524	Growth Inhibition Assay	IC50=0.55401 μM	SANGER
NCI-H526	Growth Inhibition Assay	IC50=0.63541 μM	SANGER
NCI-H64	Growth Inhibition Assay	IC50=1.28462 μM	SANGER
NCI-H69	Growth Inhibition Assay	IC50=0.80147 μM	SANGER
NCI-H716	Growth Inhibition Assay	IC50=21.3154 μM	SANGER
NCI-H719	Growth Inhibition Assay	IC50=1.17898 μM	SANGER
NCI-H720	Growth Inhibition Assay	IC50=2.16873 μM	SANGER
NCI-H747	Growth Inhibition Assay	IC50=3.05206 μM	SANGER
NCI-H748	Growth Inhibition Assay	IC50=0.10334 μM	SANGER
NCI-H82	Growth Inhibition Assay	IC50=1.63406 μM	SANGER
NCI-SNU-1	Growth Inhibition Assay	IC50=20.7223 μM	SANGER
NCI-SNU-16	Growth Inhibition Assay	IC50=15.4633 μM	SANGER
NCI-SNU-5	Growth Inhibition Assay	IC50=12.8013 μM	SANGER
NEC8	Growth Inhibition Assay	IC50=0.13527 μM	SANGER
NKM-1	Growth Inhibition Assay	IC50=0.10912 μM	SANGER
NMC-G1	Growth Inhibition Assay	IC50=0.40367 μM	SANGER
no-10	Growth Inhibition Assay	IC50=1.23112 μM	SANGER
no-11	Growth Inhibition Assay	IC50=5.76343 μM	SANGER
NOMO-1	Growth Inhibition Assay	IC50=0.81084 μM	SANGER
NOS-1	Growth Inhibition Assay	IC50=0.19619 μM	SANGER
NTERA-S-cl-D1	Growth Inhibition Assay	IC50=0.20113 μM	SANGER
OCI-AML2	Growth Inhibition Assay	IC50=3.62671 μM	SANGER
OCUB-M	Growth Inhibition Assay	IC50=1.21489 μM	SANGER
ONS-76	Growth Inhibition Assay	IC50=0.58242 μM	SANGER
OPM-2	Growth Inhibition Assay	IC50=0.41513 μM	SANGER
OS-RC-2	Growth Inhibition Assay	IC50=0.9683 μM	SANGER
OVCAR-4	Growth Inhibition Assay	IC50=1.13165 μM	SANGER
P30-OHK	Growth Inhibition Assay	IC50=17.7831 μM	SANGER
PF-382	Growth Inhibition Assay	IC50=1.11513 μM	SANGER
PSN1	Growth Inhibition Assay	IC50=1.42287 μM	SANGER
QIMR-WIL	Growth Inhibition Assay	IC50=0.68343 μM	SANGER
Raji	Growth Inhibition Assay	IC50=14.5049 μM	SANGER
Ramos-2G6-4C10	Growth Inhibition Assay	IC50=0.43897 μM	SANGER
REH	Growth Inhibition Assay	IC50=37.8211 μM	SANGER
RH-1	Growth Inhibition Assay	IC50=47.5812 μM	SANGER
RKO	Growth Inhibition Assay	IC50=3.77189 μM	SANGER
RL95-2	Growth Inhibition Assay	IC50=2.11482 μM	SANGER
RPMI-6666	Growth Inhibition Assay	IC50=0.4112 μM	SANGER
RPMI-8226	Growth Inhibition Assay	IC50=3.14378 μM	SANGER
RPMI-8402	Growth Inhibition Assay	IC50=0.38701 μM	SANGER
RPMI-8866	Growth Inhibition Assay	IC50=1.60144 μM	SANGER
RXF393	Growth Inhibition Assay	IC50=19.0186 μM	SANGER
SBC-1	Growth Inhibition Assay	IC50=1.42741 μM	SANGER
SCC-3	Growth Inhibition Assay	IC50=0.061 μM	SANGER
SCH	Growth Inhibition Assay	IC50=0.40342 μM	SANGER
SCLC-21H	Growth Inhibition Assay	IC50=1.26478 μM	SANGER
SF126	Growth Inhibition Assay	IC50=2.33094 μM	SANGER
SF268	Growth Inhibition Assay	IC50=3.48174 μM	SANGER
SF539	Growth Inhibition Assay	IC50=0.19593 μM	SANGER
SH-4	Growth Inhibition Assay	IC50=1.0241 μM	SANGER
SHP-77	Growth Inhibition Assay	IC50=4.00524 μM	SANGER
SIG-M5	Growth Inhibition Assay	IC50=0.57848 μM	SANGER
SJSA-1	Growth Inhibition Assay	IC50=1.5226 μM	SANGER
SK-LMS-1	Growth Inhibition Assay	IC50=10.2834 μM	SANGER
SK-MEL-1	Growth Inhibition Assay	IC50=8.13166 μM	SANGER
SK-MM-2	Growth Inhibition Assay	IC50=0.39868 μM	SANGER
SK-N-DZ	Growth Inhibition Assay	IC50=1.24776 μM	SANGER
SK-NEP-1	Growth Inhibition Assay	IC50=1.20266 μM	SANGER
SK-N-FI	Growth Inhibition Assay	IC50=3.45227 μM	SANGER
SK-PN-DW	Growth Inhibition Assay	IC50=0.97831 μM	SANGER
SK-UT-1	Growth Inhibition Assay	IC50=1.79388 μM	SANGER
SNB75	Growth Inhibition Assay	IC50=33.6503 μM	SANGER
SR	Growth Inhibition Assay	IC50=0.34261 μM	SANGER
ST486	Growth Inhibition Assay	IC50=0.87917 μM	SANGER
SU-DHL-1	Growth Inhibition Assay	IC50=0.65947 μM	SANGER
SW684	Growth Inhibition Assay	IC50=21.1716 μM	SANGER
SW872	Growth Inhibition Assay	IC50=1.81395 μM	SANGER
SW954	Growth Inhibition Assay	IC50=0.75999 μM	SANGER
SW962	Growth Inhibition Assay	IC50=5.38814 μM	SANGER
TE-1	Growth Inhibition Assay	IC50=0.55306 μM	SANGER
TE-10	Growth Inhibition Assay	IC50=6.42623 μM	SANGER
TE-12	Growth Inhibition Assay	IC50=3.51699 μM	SANGER
TE-15	Growth Inhibition Assay	IC50=11.6004 μM	SANGER
TE-5	Growth Inhibition Assay	IC50=3.21342 μM	SANGER
TE-8	Growth Inhibition Assay	IC50=0.36935 μM	SANGER
TE-9	Growth Inhibition Assay	IC50=1.84422 μM	SANGER
TGW	Growth Inhibition Assay	IC50=1.07675 μM	SANGER
TK10	Growth Inhibition Assay	IC50=1.83108 μM	SANGER
TUR	Growth Inhibition Assay	IC50=36.0521 μM	SANGER
U-266	Growth Inhibition Assay	IC50=2.84823 μM	SANGER
U-698-M	Growth Inhibition Assay	IC50=20.7075 μM	SANGER
U-87-MG	Growth Inhibition Assay	IC50=3.03513 μM	SANGER
UACC-257	Growth Inhibition Assay	IC50=3.43659 μM	SANGER
VA-ES-BJ	Growth Inhibition Assay	IC50=5.13778 μM	SANGER
WSU-NHL	Growth Inhibition Assay	IC50=9.77478 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03280563	Breast Neoplasms	Phase 1 Phase 2	Recruiting	October 7, 2022	-
NCT02623751	Breast Cancer	Phase 1	Active, not recruiting	February 2019	Japan ... 展开 >> Chikusa-ku, Aichi, Japan Chuo-ku, Osaka, Japan Chuo-ku, Tokyo, Japan 收起 <<
NCT00823290	Hepatocellular Carcinoma	Phase 1	Unknown	December 2010	Germany ... 展开 >> Department of Medicine 1, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Matthias Ocker, MD +49-6421-58 ext 68931 Matthias.Ocker@staff.uni-marburg.de Contact: Susanne Gahr, MD +49-9131-85 ext 35000 susanne.gahr@uk-erlangen.de Principal Investigator: Deike Strobel, MD 收起 <<
NCT01928576	Non-Small Lung Cancer, Epigene... 展开 >>tic Therapy 收起 <<	Phase 2	Recruiting	August 2022	United States, California ... 展开 >> University of Southern California Completed Los Angeles, California, United States, 90033 United States, Maryland Julie Brahmer, MD Recruiting Baltimore, Maryland, United States, 21224 Contact: Julie Brahmer, MD 410-502-7159 brahmju@jhmi.edu Contact: Jessica Wakefield 410-502-3696 jrober31@jhmi.edu Julie Brahmer, MD Recruiting Baltimore, Maryland, United States, 21287 Contact: Julie Brahmer, MD 410-502-7159 jbrahmju@jhmi.edu Contact: Jessica Wakefield 410-502-3696 jrober31@jhmi.edu United States, Pennsylvania UPMC Cancer Center- Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: James G Herman, MD 412-692-4724 hermanj3@upmc.edu 收起 <<
NCT03291886	Advanced or Recurrent Breast C... 展开 >>ancer 收起 <<	Phase 2	Active, not recruiting	November 2021	Japan ... 展开 >> Aichi Cancer Center Hospital Nagoya, Aichi, Japan Nagoya City University Hospital Nagoya, Aichi, Japan Shikoku Cancer Center Matsuyama, Ehime, Japan Kitakyushu Municipal Medical Center Kitakyushu, Fukuoka, Japan Gunma Cancer Center Ota, Gunma, Japan Hokkaido Cancer Center Sapporo, Hokkaido, Japan Hokkaido University Hospital Sapporo, Hokkaido, Japan The Hospital of Hyogo College of Medicine Nishinomiya, Hyogo, Japan Tsukuba University Hospital Tsukuba, Ibaraki, Japan Tokai University Hospital Isehara, Kanagawa, Japan Kanagawa Cancer Center Yokohama, Kanagawa, Japan Nahanishi Clinic Naha, Okinawa, Japan Kindai University Hospital Osakasayama, Osaka, Japan Osaka University Hospital Suita, Osaka, Japan Saitama Medical University International Medical Center Hidaka, Saitama, Japan Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital Bunkyo, Tokyo, Japan National Cancer Center Hospital Chuo, Tokyo, Japan The Cancer Institute Hospital of JFCR Koto, Tokyo, Japan Toranomon Hospital Minato, Tokyo, Japan Showa University Hospital Shinagawa, Tokyo, Japan Chiba Cancer Center Chiba, Japan Kyushu Cancer Center Fukuoka, Japan Sagara Hospital Kagoshima, Japan Kumamoto University Hospital Kumamoto, Japan Kyoto University Hospital Kyoto, Japan Niigata Cancer Center Hospital Niigata, Japan Okayama University Hospital Okayama, Japan Osaka National Hospital Osaka, Japan 收起 <<
NCT00185302	Melanoma	Phase 2	Completed	-	-
NCT01935947	Recurrent Non-Small Cell Lung ... 展开 >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States, 92663 United States, Maryland Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 收起 <<
NCT00020579	Cancer	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Naval Medical Center Bethesda, Maryland, United States, 20889-5000 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 收起 <<
NCT00462605	Adult Acute Lymphoblastic Leuk... 展开 >>emia in Remission Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Anemia Refractory Anemia With Excess Blasts Refractory Anemia With Ringed Sideroblasts Refractory Cytopenia With Multilineage Dysplasia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT01935947	-		Terminated	-	-
NCT00462605	-		Completed	-	-
NCT00602030	Non-Small-Cell Lung Carcinoma ... 展开 >> Carcinoma, Non-Small Cell Lung 收起 <<	Phase 1 Phase 2	Completed	-	-
NCT00015925	Leukemia Mult... 展开 >>iple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 收起 <<
NCT00828854	ER+ Breast Cancer	Phase 2	Completed	-	Ireland ... 展开 >> St. Vincent's University Hospital Dublin, Ireland United Kingdom The University of Birmingham Birmingham, United Kingdom Velindre Hospital - Whitchurch Cardiff, United Kingdom Whiston Hospital; Clatterbridge Centre for Oncology Liverpool, United Kingdom University College London Hospitals London, United Kingdom Christie Hospital, Manchester Breast Centre Manchester, United Kingdom 收起 <<
NCT00101179	Acute Myeloid Leukemia ... 展开 >> Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Leukemia Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Active, not recruiting	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, New York Mount Sinai Hospital New York, New York, United States, 10029 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT02115282	Breast Adenocarcinoma ... 展开 >> Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 收起 <<	Phase 3	Active, not recruiting	-	-
NCT00754312	Breast Cancer	Phase 1	Withdrawn(This study has been ... 展开 >>transfered from a sponsored trial to an investigator initiated trial.) 收起 <<	April 2009	United States, Indiana ... 展开 >> Monet Bowling, MD Indianapolis, Indiana, United States 收起 <<
NCT03215264	Colorectal Cancer	Phase 1 Phase 2	Recruiting	July 10, 2020	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Peter O'Dwyer, MD 855-216-0098 PennCancerTrials@emergingmed.com Principal Investigator: Peter O'Dwyer, MD 收起 <<
NCT00098891	Adult Grade III Lymphomatoid G... 展开 >>ranulomatosis Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenström Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT00750698	Non Small Cell Lung Cancer	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States University of California San Diego La Jolla, California, United States Sharp Memorial Hospital San Diego, California, United States United States, Florida University of Miami, Miller School of Medicine Miami, Florida, United States United States, Georgia Medical College of Georgia Augusta, Georgia, United States United States, Illinois RUSH University Medical Center Chicago, Illinois, United States United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States United States, Minnesota the Mayo Clinic Rochester, Minnesota, United States United States, New York Roswell Park Cancer Institute Buffalo, New York, United States United States, North Carolina Blumenthal Cancer Center Charlotte, North Carolina, United States United States, South Carolina University of South Carolina Charleston, South Carolina, United States South Carolina Oncology Associates Columbia, South Carolina, United States 收起 <<
NCT00313586	-		Completed	-	-
NCT03250273	Previously Treated Unresectabl... 展开 >>e or Metastatic Cholangiocarcinoma and Pancreatic Cancer Cholangiocarcinoma Pancreatic Cancer Metastatic Pancreatic Cancer 收起 <<	Phase 2	Recruiting	November 2020	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21231 Contact: Susan Sartorius-Mergenthaler, RN 410-614-3644 Sartosu@jhmi.edu Contact: Jane Zorzi, RN 410-614-5818 Jzorzi1@jhmi.edu 收起 <<
NCT01207726	Stage IA Non-Small Cell Lung C... 展开 >>arcinoma Stage IB Non-Small Cell Lung Carcinoma 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Maryland Anne Arundel Medical Center Annapolis, Maryland, United States, 21401 Greater Baltimore Medical Center Baltimore, Maryland, United States, 21204 Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT02115594	Breast Cancer	Phase 2	Withdrawn(Internal decision)	June 2016	United States, Tennessee ... 展开 >> Tennessee Oncololgy Nashville, Tennessee, United States, 37203 收起 <<
NCT00313586	Acute Myeloid Leukemia Arising... 展开 >> From Previous Myelodysplastic Syndrome Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA Alkylating Agent-Related Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	-
NCT02697630	Metastatic Uveal Melanoma	Phase 2	Recruiting	August 2023	Sweden ... 展开 >> Department of oncology, Sahlgrenska University Hospital Recruiting Gothenburg, Västra Götaland Region, Sweden, SE-413 45 Contact: Lars Ny, Doctor + 46 31 342 10 00 lars.ny@vgregion.se 收起 <<
NCT01038778	Clear Cell Renal Cell Carcinom... 展开 >>a Metastatic Renal Cell Cancer Stage III Renal Cell Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT01159301	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Recurrent Adult Acute Myeloid Leukemia Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01349959	Estrogen Receptor Negative ... 展开 >> Estrogen Receptor Positive HER2/Neu Negative Male Breast Carcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Triple-Negative Breast Carcinoma 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Minnesota Unity Hospital Fridley, Minnesota, United States, 55432 Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States, 55416 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT01886573	Stage IA Non-Small Cell Lung C... 展开 >>arcinoma Stage IB Non-Small Cell Lung Carcinoma Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer 收起 <<	Phase 1	Terminated	-	United States, Kentucky ... 展开 >> University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87106 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT01349959	-		Completed	-	-
NCT01105377	Recurrent Colon Cancer ... 展开 >> Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California University of Southern California/Norris Cancer Center Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Maryland Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota, United States, 55109 Mayo Clinic Rochester, Minnesota, United States, 55905 Metro-Minnesota CCOP Saint Louis Park, Minnesota, United States, 55416 United Hospital Saint Paul, Minnesota, United States, 55102 Lakeview Hospital Stillwater, Minnesota, United States, 55082 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT01305499	Acute Myeloid Leukemia	Phase 2	Recruiting	February 2019	United States, Connecticut ... 展开 >> Yale School of Medicine Not yet recruiting New Haven, Connecticut, United States, 06520 Contact: Steven Gore, MD steven.gore@yale.edu United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231 United States, Ohio Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Not yet recruiting Cleveland, Ohio, United States, 44106 Contact: Benjamin Tomlinson, MD Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Hetty Carraway, MD, MBA 216-445-5899 carrawh@ccf.org 收起 <<
NCT01132573	Acute Leukemias of Ambiguous L... 展开 >>ineage Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado Anschutz Medical Campus Aurora, Colorado, United States, 80045 University of Colorado Denver, Colorado, United States, 80217-3364 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 收起 <<
NCT01105377	-		Completed	-	-
NCT00676663	Breast Cancer ... 展开 >> Estrogen Receptor-Positive Breast Cancer Breast Cancer, Estrogen Receptor-Positive ER+ Breast Cancer 收起 <<	Phase 2	Completed	-	-
NCT03538171	Advanced Breast Cancer	Phase 3	Recruiting	April 2023	China, Beijing ... 展开 >> Cancer Hospital Chinese Academy Medical Sciences Recruiting Beijing, Beijing, China, 10021 Contact: Binghe Xu, Ph D 收起 <<
NCT00387465	Recurrent Non-Small Cell Lung ... 展开 >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Sidney Kimmel Cancer Center San Diego, California, United States, 92121 United States, Maryland Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 收起 <<
NCT03018249	Grade 1 Endometrial Endometrio... 展开 >>id Adenocarcinoma Grade 2 Endometrial Endometrioid Adenocarcinoma Grade 3 Endometrial Endometrioid Adenocarcinoma Uterine Corpus Adenosarcoma 收起 <<	Phase 2	Active, not recruiting	December 31, 2020	-
NCT01383447	Philadelphia Chromosome Positi... 展开 >>ve Adult Precursor Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia 收起 <<	Phase 1 Phase 2	Terminated(This study was halt... 展开 >>ed prematurely by the NCI for low accrual.) 收起 <<	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT02453620	Breast Adenocarcinoma ... 展开 >> HER2/Neu Negative Invasive Breast Carcinoma Metastatic Malignant Solid Neoplasm Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Site Public Contact 800-826-4673 becomingapatient@coh.org Principal Investigator: Vincent Chung United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Patricia M. LoRusso Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Patricia M. LoRusso United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Roisin M. Connolly United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Adam M. Brufsky 收起 <<
NCT01434303	HER2/Neu Positive ... 展开 >> Invasive Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7 收起 <<	Phase 1	Active, not recruiting	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01234532	Estrogen Receptor-negative Bre... 展开 >>ast Cancer HER2-negative Breast Cancer Progesterone Receptor-negative Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Triple-negative Breast Cancer 收起 <<	Phase 2	Terminated(low accrual)	-	United States, Maryland ... 展开 >> University of Maryland Baltimore Baltimore, Maryland, United States, 21201 收起 <<
NCT02437136	Non-Small Cell Lung Cancer ... 展开 >> Melanoma Mismatch Repair-Proficient Colorectal Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	August 2019	United States, Connecticut ... 展开 >> Yale University New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Maryland University of Maryland, Marlene and Stewart Greenbaum Cancer Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana Farber Cancer Institution Boston, Massachusetts, United States, 02215 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania St Luke's University Health Network Easton, Pennsylvania, United States, 18045 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Vanderbilt University Medical Center Nashville, Tennessee, United States, 37230 收起 <<
NCT03024437	Metastatic Cancer ... 展开 >> Renal Cancer 收起 <<	Phase 1 Phase 2	Recruiting	January 31, 2020	United States, Indiana ... 展开 >> Indiana University Health Hospital Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sheila Dropcho, RN 317-278-4191 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD Indiana University Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sheila Dropcho, RN 317-278-4191 sdropcho@iupui.edu Principal Investigator: Roberto Pili, MD United States, Pennsylvania University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Julia Wolinkski 215-360-0928 julia.wolinksi@uphs.upenn.edu Principal Investigator: Vivek Narayan, MD 收起 <<
NCT01594398	Lung Cancer N... 展开 >>on Small Cell Lung Cancer (NSCLC) Breast Cancer Estrogen Receptor Breast Cancer 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Oklahoma Peggy and Charles Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 收起 <<
NCT01383447	-		Terminated(This study was halt... 展开 >>ed prematurely by the NCI for low accrual.) 收起 <<	-	-
NCT03501381	Renal Cell Carcinoma	Phase 2	Recruiting	April 2023	United States, Indiana ... 展开 >> Indiana Univeristy Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-278-7776 rpili@iu.edu Principal Investigator: Roberto Pili, MD United States, Nebraska Nebraska Methodist Hospital Recruiting Omaha, Nebraska, United States, 68114 Contact: Craig Ryan craig.ryan@nmhs.org Principal Investigator: Ralph Hauke, MD 收起 <<
NCT00866333	Hodgkin's Lymphoma	Phase 2	Completed	-	United States, California ... 展开 >> Tower Cancer Research Foundaton Beverly Hills, California, United States United States, Colorado University of Colorado Denver, Colorado, United States United States, Maryland Johns Hopkins Baltimore, Maryland, United States United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States United States, New York Roswell Park Cancer Institute Buffalo, New York, United States United States, Texas MD Anderson Cancer Center Houston, Texas, United States 收起 <<
NCT02909452	Neoplasms Neo... 展开 >>plasms, Glandular and Epithelial Neoplasms by Histologic Type Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Digestive System Neoplasms Endocrine Gland Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors 收起 <<	Phase 1	Active, not recruiting	February 2019	United States, Texas ... 展开 >> The START Center for Cancer Care San Antonio, Texas, United States, 78229 收起 <<
NCT02780804	Childhood Brain Stem Neoplasm ... 展开 >> Childhood Lymphoma Childhood Solid Neoplasm Pineal Region Neoplasm Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Visual Pathway Glioma Refractory Central Nervous System Neoplasm 收起 <<	Phase 1	Recruiting	-	-
NCT02936752	Blasts 21-30 Percent of Bone M... 展开 >>arrow Nucleated Cells Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome 收起 <<	Phase 1	Recruiting	June 30, 2019	United States, Connecticut ... 展开 >> Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Amer M. Zeidan Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Amer M. Zeidan United States, Kentucky University of Kentucky/Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Site Public Contact 859-257-3379 Principal Investigator: Reshma Ramlal United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese 收起 <<
NCT02820961	Breast Cancer ... 展开 >> Estrogen Receptor Positive Breast Cancer 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, Colorado ... 展开 >> Sarah Cannon Research Institute HealthONE Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 收起 <<
NCT03765229	Melanoma	Phase 2	Not yet recruiting	June 2023	-
NCT03179930	Lymphoma Rela... 展开 >>psed Refractory 收起 <<	Phase 2	Recruiting	June 2019	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Anas Younes, MD 212-639-7715 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Anas Younes, MD 212-639-7715 Contact: Allison Moskowitz, MD 212-639-4839 Principal Investigator: Anas Younes, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Anas Younes, MD 212-639-7715 收起 <<
NCT02922933	Volunteers He... 展开 >>althy Volunteers Human Volunteers Normal Volunteers 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Celerion Tempe, Arizona, United States, 85283 United States, Nebraska Celerion Lincoln, Nebraska, United States, 68502 收起 <<
NCT02708680	Breast Cancer	Phase 1 Phase 2	Active, not recruiting	January 2020	-
NCT03211988	Neuroendocrine Tumors	Phase 2	Recruiting	August 2021	United States, New York ... 展开 >> Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Edward Gelmann, MD eg2359@cumc.columbia.edu 收起 <<
NCT03552380	Renal Cell Carcinoma	Phase 2	Recruiting	August 2020	United States, Indiana ... 展开 >> Indiana Univeristy Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-278-7776 rpili@iu.edu Principal Investigator: Roberto Pili, MD 收起 <<
NCT03473639	Metastatic Breast Cancer ... 展开 >> Breast Cancer 收起 <<	Phase 1	Recruiting	October 15, 2028	United States, Virginia ... 展开 >> University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Sue Jones, BSN, RN, OCN, CCRP 44 924 9199 syt8a@virginia.edu Principal Investigator: Patrick Dillon, MD 收起 <<
NCT03361800	Breast Cancer ... 展开 >> Invasive Breast Cancer ER-Negative PR-Negative HER2-Negative Breast Cancer 收起 <<	Early Phase 1	Recruiting	February 15, 2019	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Camilla Brewer 919-966-4432 camilla_brewer@med.unc.edu Contact: Katie Lansing 919-966-4432 kathryn_lansing@med.unc.edu 收起 <<
NCT02833155	Breast Cancer	Phase 1	Recruiting	September 2018	China, Beijing ... 展开 >> Cancer Hospital Chinese Academy Medical Sciences Recruiting Beijing, Beijing, China, 100021 Contact: Jingjing Wang +8615010581751 China, Hunan Hunan Cancer Hospital Not yet recruiting Changsha, Hunan, China, 410013 China, Sichuan West China Hospital Not yet recruiting Chengdu, Sichuan, China, 610041 Contact: Hong Zheng, MD China, Tianjin Tianjin Medical University Cancer Institute & Hospital Not yet recruiting Tianjin, Tianjin, China, 300000 收起 <<
NCT03760614	Pancreas Cancer	Phase 1	Not yet recruiting	November 2020	-
NCT03187015	Drug Interaction ... 展开 >> Healthy Volunteer 收起 <<	Phase 1	Completed	-	United States, Nebraska ... 展开 >> Celerion Lincoln, Nebraska, United States, 68502 收起 <<
NCT03192111	Renal Impairment ... 展开 >> Healthy Volunteer 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Clinical Pharmacology of Miami Miami, Florida, United States, 33014 Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Tennessee New Orleans Center for Clinical Research Knoxville, Tennessee, United States, 37920 收起 <<
NCT02915523	Epithelial Ovarian Cancer ... 展开 >> Peritoneal Cancer Fallopian Tube Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	March 2021	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Tampa, Florida, United States, 33612 Florida Cancer Specialist East Region (SCRI Affiliate) West Palm Beach, Florida, United States, 33401 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland Greater Baltimore Medical Center Baltimore, Maryland, United States, 21204 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Missouri HCA Midwest Health (SCRI Affiliate) Kansas City, Missouri, United States, 64131 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37204 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 收起 <<
NCT02922946	Volunteers He... 展开 >>althy Volunteers Human Volunteers Normal Volunteers 收起 <<	Phase 1	Completed	-	United States, Nebraska ... 展开 >> Celerion Lincoln, Nebraska, United States, 68502 收起 <<
NCT02897778	Neoplasms Neo... 展开 >>plasms, Glandular and Epithelial Neoplasms by Histologic Type Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Digestive System Neoplasms Endocrine Gland Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases Breast Neoplasms Breast Diseases Renal Neoplasm Solid Tumors 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> The START Center for Cancer Care San Antonio, Texas, United States, 78229 收起 <<

Entinostat/恩替诺特 {[allProObj[0].p_purity_real_show]}

Entinostat/恩替诺特纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Entinostat/恩替诺特质控信息

Entinostat/恩替诺特生物活性

Entinostat/恩替诺特细胞实验

Entinostat/恩替诺特动物实验

Entinostat/恩替诺特动物研究

Entinostat/恩替诺特临床研究

Entinostat/恩替诺特参考文献

Entinostat/恩替诺特实验方案

Entinostat/恩替诺特技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Entinostat/恩替诺特 {[allProObj[0].p_purity_real_show]}

Entinostat/恩替诺特 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Entinostat/恩替诺特 质控信息

Entinostat/恩替诺特 生物活性

Entinostat/恩替诺特 细胞实验

Entinostat/恩替诺特 动物实验

Entinostat/恩替诺特 动物研究

Entinostat/恩替诺特 临床研究

Entinostat/恩替诺特 参考文献

Entinostat/恩替诺特 实验方案

Entinostat/恩替诺特 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Entinostat/恩替诺特纯度/质量文件产品仅供科研

Entinostat/恩替诺特质控信息

Entinostat/恩替诺特生物活性

Entinostat/恩替诺特细胞实验

Entinostat/恩替诺特动物实验

Entinostat/恩替诺特动物研究

Entinostat/恩替诺特临床研究

Entinostat/恩替诺特参考文献

Entinostat/恩替诺特实验方案

Entinostat/恩替诺特技术信息